Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacement
Open Access
- 13 December 2005
- journal article
- research article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 4 (1), 121-128
- https://doi.org/10.1111/j.1538-7836.2005.01657.x
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitorCancer Cell, 2005
- New anticoagulants: beyond heparin, low‐molecular‐weight heparin and warfarinBritish Journal of Pharmacology, 2005
- In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitorJournal of Thrombosis and Haemostasis, 2005
- Prevention of Venous Thromboembolism Among Hospitalized Medical PatientsCirculation, 2005
- A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trialJournal of Thrombosis and Haemostasis, 2005
- Prevention of Venous ThromboembolismChest, 2004
- Current anticoagulant therapy—unmet clinical needsThrombosis Research, 2003
- Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trialThe Lancet, 2002
- A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis after Total Hip ReplacementNew England Journal of Medicine, 2001
- Roentgen Diagnosis of Venous Thrombosis in the LegArchives of Surgery, 1972